NCT03003650已完成不适用
ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis:CE-approval Cohort
Symetis SA11 个研究点 分布在 3 个国家目标入组 89 人开始时间: 2011年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 89
- 试验地点
- 11
- 主要终点
- Freedom from all-cause mortality
研究概览
简要总结
First clinical experience on the ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation in Patients with Severe Aortic Stenosis to collect human data pertaining to the safety and performance of the device from three different cohorts
详细描述
A prospective, multicenter, "CE-approval cohort" analysis with the Symetis ACURATE TF™ Transfemoral Aortic Bioprosthesis for minimal invasive implantation via transfemoral access to treat patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open heart surgery is considered to be associated with high risk, to evaluate the feasibility and performance of the implantation at 30-Days and at 1-Year Follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 75 years of age and older
- •Logistic EuroSCORE ≥ 20%
- •Severe aortic stenosis characterized by mean aortic gradient > 40 mmHg or peak jet velocity > 4.0 m/s or aortic valve area of < 1.0 cm2
- •New York Heart Association (NYHA) Functional Class > II
- •Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by Trans-esophageal Echocardiography (TEE)
- •Patient not a surgical candidate due to significant co-morbid conditions unrelated to aortic stenosis
- •Patient willing to participate in the study and provide signed informed consent
排除标准
- •Unicuspid or bicuspid aortic valve
- •Extreme eccentricity of calcification
- •Severe mitral regurgitation ( >2+)
- •Pre-existing prosthetic heart valve in any position and / or prosthetic ring
- •Aortic or peripheral anatomy NOT appropriate for transfemoral implant
- •Thoracic (TAA) or abdominal (AAA) aortic aneurysm
- •Presence of endovascular stent graft for treatment of TAA or AAA
- •TEE is contraindicated
- •Left Ventricular Ejection Fraction (LVEF) < 30% by echocardiography (ECHO)
- •ECHO evidence of intracardiac mass, thrombus, or vegetation
- •Acute Myocardial Infarction (AMI) within 1 month prior to implant procedure
- •Percutaneous Coronary Intervention (PCI), except for balloon valvuloplasty (BAV) within 1 month prior to implant procedure
- •Previous Transien Ischemic Attack (TIA) or stroke within 3 months prior to implant procedure
- •Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant procedure
- •Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit
- •History of bleeding diathesis or coagulopathy or refusal of blood transfusions
- •Systolic pressure <80 mmHg, cardiogenic shock, need for inotropic support or Intra-Aortic Balloon Pump (IABP)
- •Primary hypertrophic obstructive cardiomyopathy (HOCM)
- •Active infection, endocarditis or pyrexia
- •Hepatic failure
- •Chronic renal dysfunction with serum creatinine > 2.5 mg/dL or renal dialysis
- •Refusal of surgery
- •Severe Chronic Obstructive Pulmonary Disease (COPD) requiring home oxygen
- •Neurological disease severely affecting ambulation or daily functioning, or dementia
- •Life expectancy < 12 months due to non-cardiac co-morbid conditions
- •Known hypersensitivity/contraindication to study medication, contrast media, or nitinol
- •Currently participating in an investigational drug or another device study
研究组 & 干预措施
Symetis ACURATE TF™
Experimental
Patient implanted with ACURATE TF™Bioprosthesis.
干预措施: ACURATE TF™ (Device)
结局指标
主要结局
Freedom from all-cause mortality
时间窗: 30-Day Follow-up
Rate of all-cause mortality
次要结局
- Rate of MACCE (major cardiac and cerebrovascular event) related to the ACURATE TF™ Transfemoral Aortic Bioprosthesis and Delivery System.(30-Days and 12 Months Follow-up)
- Change in NYHA class over time(30-Day and 12-Month)
- Procedural success during device implantation(intraoperative)
- Device success(30-Day and 12-Month Follow-up)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
不适用
ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2011-03)Aortic Stenosis SymptomaticNCT03752996Symetis SA140
已完成
3 期
ACURATE TF Transfemoral Aortic Bioprosthesis for Implantation in patients with severe aortic stenosisI35.0Aortic (valve) stenosisDRKS00013491Symetis SA39
已完成
不适用
ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic StenosisAortic StenosisNCT02986737Symetis SA15
撤回
不适用
ACURATE TA* Transapical Aortic Bioprosthesis for Implantation in Patients with Severe Aortic StenosisSevere Aortic Stenosis1008220610003216NL-OMON37451SYMETIS S.A.10
已完成
不适用
ACURATE TA™ Valve Implantation Registry: SAVI 2Aortic StenosisNCT02663375Symetis SA250